Insight Molecular Diagnostics Inc. — Director's Dealing 2015

Dec 31, 2015

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2015-12-30

Reporting Person: KINGSLEY ALFRED D (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, no par value	296902	Direct
Common Stock, no par value	75345	Indirect
Common Stock, no par value	18767	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Stock	$1.34	2020-12-28	Common Stock (125000)		Direct
Option to Purchase Common Stock	$2.20	2025-01-08	Common Stock (75000)		Direct

Footnotes

F1: 1/48th of the number of options vested and became exercisable at the end of each full month after the date of grant on December 29, 2010.

F2: One quarter of these options will vest and thereby become exercisable one year from the date of grant, and the balance will vest in equal 36 monthly
installments commencing on the first anniversary date of the grant.